Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
The drug, an injectable taken once a week, helped patients on the highest dose lose 15.3% of their body weight on average and lower their blood sugar by 1.9% over nine months
15-24% at diabetes doses), vomiting, diarrhea, constipation, and abdominal discomfort, which may be difficult to distinguish from neurogenic bowel dysfunction in MS patients [11] [3] Fatigue : Reported in clinical trials and potentially additive to MS-related fatigue, one of the most disabling MS symptoms Dizziness : May occur due to blood pressure changes or dehydration, overlapping with MS-related balance and vestibular symptoms Weight loss induced by tirzepatidewhile therapeutically beneficial for metabolic healthrequires monitoring in MS patients, as unintentional or excessive weight loss could affect mobility, muscle strength, and overall functional status
How should these products be used
Patients repeatedly praise MEDVi clinical staff for being knowledgeable, responsive, and genuinely attentive to individual concerns
Compounded formulations have not been independently studied for these effects
SURMOUNT-1 Trial Data for Tirzepatide The SURMOUNT-1 trial (N=2,539) tested tirzepatide, a dual GIP/GLP-1 receptor agonist, in adults with obesity but without type 2 diabetes
